08.01.11j, Ado-Trastuzumab Emtansine (Kadcyla®)

By November 17, 2025: Billing and clinical teams must obtain and review the complete updated policy text from the source URL to identify specific medical necessity criteria and coding changes for Kadcyla® (Ado-Trastuzumab Emtansine). Update billing system rules and provider documentation templates accordingly. Coordinate with oncology providers to ensure all Kadcyla® claims include required medical necessity documentation per the new criteria. Monitor initial claims submissions for denials and adjust processes as needed. Note: Specific billing codes and detailed requirements cannot be extracted from the policy metadata provided; the full policy text must be reviewed directly.